GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » Price-to-Owner-Earnings

Egetis Therapeutics AB (OSTO:EGTX) Price-to-Owner-Earnings : (As of May. 18, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB Price-to-Owner-Earnings?

As of today (2024-05-18), Egetis Therapeutics AB's share price is kr7.00. Egetis Therapeutics AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Egetis Therapeutics AB's Price-to-Owner-Earnings or its related term are showing as below:


OSTO:EGTX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-18), Egetis Therapeutics AB's share price is kr7.00. Egetis Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-1.20. Therefore, Egetis Therapeutics AB's PE Ratio for today is At Loss.

As of today (2024-05-18), Egetis Therapeutics AB's share price is kr7.00. Egetis Therapeutics AB's EPS without NRI for the trailing twelve months (TTM) ended in was kr-1.20. Therefore, Egetis Therapeutics AB's PE Ratio without NRI for today is At Loss.


Egetis Therapeutics AB Price-to-Owner-Earnings Historical Data

The historical data trend for Egetis Therapeutics AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Price-to-Owner-Earnings Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Egetis Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Egetis Therapeutics AB's Price-to-Owner-Earnings

For the Biotechnology subindustry, Egetis Therapeutics AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Price-to-Owner-Earnings falls into.



Egetis Therapeutics AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Egetis Therapeutics AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=7.00/-0.93
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Egetis Therapeutics AB  (OSTO:EGTX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Egetis Therapeutics AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB (OSTO:EGTX) Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB (OSTO:EGTX) Headlines

No Headlines